Pharmacotherapy for childhood obesity: present and future prospects
暂无分享,去创建一个
S. Yanovski | J. Yanovski | R Sherafat-Kazemzadeh | S Z Yanovski | J A Yanovski | R. Sherafat‐Kazemzadeh | R. Sherafat-Kazemzadeh
[1] Ahmad Al Rousan. Middle east review , 2007 .
[2] Bacon Ge,et al. A clinical trial of fenfluramine in obese children. , 1967 .
[3] D. Chlebna-Sokół,et al. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)]. , 1981, Przeglad lekarski.
[4] B. Barton,et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. , 2006, The American journal of psychiatry.
[5] C. Weyer,et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. , 2003, Metabolism: clinical and experimental.
[6] Paul Webb,et al. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight , 2004, Trends in Endocrinology & Metabolism.
[7] Dong-Chul Seo,et al. A meta-analysis of obesity interventions among U.S. minority children. , 2010, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.
[8] K. Gadde,et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.
[9] S. Inzucchi,et al. Metformin: new understandings, new uses. , 2003, Drugs.
[10] K. Westerterp,et al. The effect of sibutramine on energy expenditure and body composition in obese adolescents. , 2007, Journal of Clinical Endocrinology and Metabolism.
[11] S. Gahagan,et al. Overweight and Obesity , 2011 .
[12] F. de Zegher,et al. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. , 2004, The Journal of clinical endocrinology and metabolism.
[13] Darrell M. Wilson. Analysis of metformin treatment for adolescent obesity at 48 rather than 24 weeks after treatment cessation. , 2010 .
[14] J. Rosenstock,et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.
[15] J. McNeil,et al. Pharmacotherapies for Obesity: Past, Current, and Future Therapies , 2010, Journal of obesity.
[16] W. Edwards,et al. Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.
[17] L. Baur,et al. Adiposity and body mass indices in children: Benn's index and other weight for height indices as measures of relative adiposity. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[18] K. Westerterp,et al. Short-term effects of growth hormone on body composition as a predictor of growth. , 2003, The Journal of clinical endocrinology and metabolism.
[19] A. Astrup. Thermogenic drugs as a strategy for treatment of obesity , 2000, Endocrine.
[20] A. Astrup,et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.
[21] M. Maffei,et al. Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.
[22] M. Trautmann,et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years , 2011, BMC endocrine disorders.
[23] D. Giugliano,et al. Pharmacokinetic-Pharmacodynamic Relationships of Acarbose , 1996, Clinical pharmacokinetics.
[24] K. Rice,et al. Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.
[25] A. Grüters,et al. Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study. , 2010, European journal of endocrinology.
[26] M. Schwartz,et al. Elevated plasma ghrelin levels in Prader–Willi syndrome , 2002, Nature Medicine.
[27] R. Krauss,et al. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins , 2008, Proceedings of the National Academy of Sciences.
[28] Mary T. Brinkoetter,et al. Leptin is an effective treatment for hypothalamic amenorrhea , 2011, Proceedings of the National Academy of Sciences.
[29] K. Gadde,et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. , 2002, Obesity research.
[30] V. Hubbard,et al. Efficacy of Orlistat as an Adjunct to Behavioral Treatment in Overweight African American and Caucasian Adolescents with Obesity-related Co-morbid Conditions , 2004, Journal of pediatric endocrinology & metabolism : JPEM.
[31] H. Chase,et al. A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 Diabetes , 2009, Pediatrics.
[32] C. Mantzoros,et al. Efficacy of Metreleptin in Obese Patients With Type 2 Diabetes: Cellular and Molecular Pathways Underlying Leptin Tolerance , 2011, Diabetes.
[33] R. Baldessarini,et al. Open trial of bupropion SR in adolescent major depression. , 2003, Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc.
[34] C. Winick,et al. Three controlled trials of weight loss with phenylpropanolamine. , 1982, International journal of obesity.
[35] J. Kullberg,et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. , 2012, The Journal of clinical endocrinology and metabolism.
[36] S. Heymsfield,et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. , 2007, The Journal of clinical endocrinology and metabolism.
[37] Arya M. Sharma,et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. , 2010, The New England journal of medicine.
[38] M. Cowley,et al. Inhibition of Dopamine and Norepinephrine Reuptake Produces Additive Effects on Energy Balance in Lean and Obese Mice , 2007, Neuropsychopharmacology.
[39] M. Schwartz. Brain Pathways Controlling Food Intake and Body Weight , 2001, Experimental biology and medicine.
[40] D. Stewart,et al. Tenuate dospan as an appetitie suppressant in the treatment of obese children. , 1970, Applied therapeutics.
[41] A. Halpern,et al. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. , 1996, Obesity research.
[42] D. Boulton,et al. Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects , 2009, Clinical pharmacology and therapeutics.
[43] D. Matthews,et al. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.
[44] D. Lackland,et al. Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Meta , 2005, The American journal of the medical sciences.
[45] S. Dakhli,et al. [Obesity in children]. , 2000, La Tunisie medicale.
[46] Zhengyan Zhao,et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention , 2007, International Journal of Obesity.
[47] L. Epstein,et al. Growth in obese children treated for obesity. , 1990, American journal of diseases of children.
[48] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.
[49] P. Tønnesen,et al. The effect of ephedrine plus caffeine on smoking cessation and postcessation weight gain * , 1996, Clinical pharmacology and therapeutics.
[50] W. Poston,et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials , 2002, International Journal of Obesity.
[51] J. Rosenstock,et al. Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes , 2010, Diabetes Care.
[52] T. Cole,et al. What is the best measure of adiposity change in growing children: BMI, BMI %, BMI z-score or BMI centile? , 2005, European Journal of Clinical Nutrition.
[53] Leonard H Epstein,et al. Family-based obesity treatment, then and now: twenty-five years of pediatric obesity treatment. , 2007, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[54] S. O’Rahilly,et al. Congenital leptin deficiency due to homozygosity for the Delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. , 2004, The Journal of clinical endocrinology and metabolism.
[55] B. Zinman,et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)) , 2010 .
[56] A. Astrup,et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men , 2010, International Journal of Obesity.
[57] S. Del Prato,et al. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. , 2013, Deutsche medizinische Wochenschrift.
[58] Darrell M. Wilson,et al. Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. , 2010, Archives of pediatrics & adolescent medicine.
[59] T. Sørensen,et al. Childhood body-mass index and the risk of coronary heart disease in adulthood. , 2008, The New England journal of medicine.
[60] M. Krotkiewski. Thyroid hormones and treatment of obesity , 2000, International Journal of Obesity.
[61] T. Pischon,et al. Recent developments in the treatment of obesity-related hypertension , 2002, Current opinion in nephrology and hypertension.
[62] U. Ekelund,et al. Genetic Susceptibility to Obesity and Related Traits in Childhood and Adolescence , 2010, Diabetes.
[63] M. Forrester. Pattern of orlistat exposures in children aged 5 years or less. , 2009, The Journal of emergency medicine.
[64] K. Gadde,et al. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. , 2007, The Journal of clinical psychiatry.
[65] D. Vukovic. [Obesity in childhood]. , 1972, Srpski Arhiv za Celokupno Lekarstvo.
[66] D. Molnár,et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents , 2000, International Journal of Obesity.
[67] A. Haqq,et al. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. , 2003, The Journal of clinical endocrinology and metabolism.
[68] Corby K. Martin,et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. , 2011, Journal of Clinical Endocrinology and Metabolism.
[69] R. Canitano. Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders , 2005, Brain and Development.
[70] J. Lorber. Obesity in childhood. A controlled trial of anorectic drugs. , 1966, Archives of disease in childhood.
[71] P. Mirmiran,et al. Childhood obesity in the Middle East: a review. , 2010, Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit.
[72] S. Toubro,et al. Effects of the two β3-agonists, ZD7114 and ZD2079 on 24 hour energy expenditure and respiratory quotient in obese subjects , 2000, International Journal of Obesity.
[73] B. Bode,et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.
[74] C. Weyer,et al. Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats , 2008, International Journal of Obesity.
[75] K. Flegal,et al. Prevalence of high body mass index in US children and adolescents, 2007-2008. , 2010, JAMA.
[76] Robin Christensen,et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials , 2007, The Lancet.
[77] M. Boldrin,et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. , 2005, JAMA.
[78] J. Spranger. [Phentermine resinate in obesity. Clinical trial of Mirapront in adipose children]. , 1965, Münchener medizinische Wochenschrift.
[79] Christian Weyer,et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies , 2008, Proceedings of the National Academy of Sciences.
[80] J. Rutledge,et al. Multinutrient supplement containing ephedra and caffeine causes weight loss and improves metabolic risk factors in obese women: a randomized controlled trial , 2006, International Journal of Obesity.
[81] M. Lesch,et al. Sudden death associated with thyroid hormone abuse. , 1981, The American journal of medicine.
[82] F. Karlsson,et al. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. , 2003 .
[83] T. Lutz,et al. Brainstem mechanisms of amylin-induced anorexia , 2010, Physiology & Behavior.
[84] A. Hokken-Koelega,et al. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. , 2006, The Journal of clinical endocrinology and metabolism.
[85] K. Gadde,et al. Rational Design of a Combination Medication for the Treatment of Obesity , 2009, Obesity.
[86] G. Colditz,et al. Adiposity in adolescents: change in actual BMI works better than change in BMI z score for longitudinal studies. , 2007, Annals of epidemiology.
[87] P. O'Neil,et al. Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.
[88] A. Berkenstam,et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans , 2008, Proceedings of the National Academy of Sciences.
[89] S. Garattini,et al. Neurochemical mechanism of action of anorectic drugs. , 1993, Pharmacology & toxicology.
[90] M. Worsham,et al. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. , 1997, MMWR. Morbidity and mortality weekly report.
[91] A. Powell. Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2012 .
[92] Masahiko Watanabe,et al. Peripheral, but Not Central, CB1 Antagonism Provides Food Intake–Independent Metabolic Benefits in Diet-Induced Obese Rats , 2008, Diabetes.
[93] B. Beech,et al. Attrition in paediatric weight management: a review of the literature and new directions , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[94] H. Chase,et al. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. , 2009, The Journal of pediatrics.
[95] G. Lowrey,et al. A clinical trial of fenfluramine in obese children. , 1967, Current therapeutic research, clinical and experimental.
[96] Graham M Lord,et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. , 2002, The Journal of clinical investigation.
[97] D. Guzick,et al. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. , 2008, The Journal of clinical endocrinology and metabolism.
[98] Katherine H. Pavlovich,et al. Effects of experimental weight perturbation on skeletal muscle work efficiency, fuel utilization, and biochemistry in human subjects. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.
[99] D. Simons-Morton,et al. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2011, Pediatrics.
[100] G. Bray,et al. Treatment of hypothalamic obesity with caffeine and ephedrine. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[101] M. Nauck. Liraglutide, a once-daily human GLP-1 analogue , 2008 .
[102] E. Diamanti-Kandarakis,et al. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. , 2006, Fertility and sterility.
[103] K. Fujioka,et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. , 1999, JAMA.
[104] K. Yoon,et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial , 2011, Diabetes, obesity & metabolism.
[105] C. Lämmer,et al. [Changes in carbohydrate metabolism and insulin resistance in patients with Prader-Willi Syndrome (PWS) under growth hormone therapy]. , 2007, Wiener medizinische Wochenschrift.
[106] A. Vaag,et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.
[107] D. Schlundt,et al. Evaluation of the insulin resistance syndrome in 5- to 10-year-old overweight/obese African-American children. , 2001, Diabetes care.
[108] S. Norgren,et al. Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. , 2007, The Journal of clinical endocrinology and metabolism.
[109] L. Meacham,et al. The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. , 2002, Archives of pediatrics & adolescent medicine.
[110] S. Heymsfield,et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. , 2005, The Journal of clinical investigation.
[111] W. Dietz,et al. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. , 1992, The New England journal of medicine.
[112] A. Astrup,et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.
[113] J. Purnell,et al. Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet. , 2003, The Journal of clinical endocrinology and metabolism.
[114] A. Belza,et al. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects , 2007, International Journal of Obesity.
[115] Topiramate for weight reduction in duchenne muscular dystrophy , 2005, Muscle & nerve.
[116] G G Enas,et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. , 1994, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[117] N. Lehmann,et al. Effects of Growth Hormone Therapy on Cardiac Dimensions in Children and Adolescents with Prader-Willi Syndrome , 2010, Hormone Research in Paediatrics.
[118] S. Toubro,et al. Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[119] William Caplan,et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. , 2007, Journal of the American Dietetic Association.
[120] R R Wing,et al. Ten-year outcomes of behavioral family-based treatment for childhood obesity. , 1994, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[121] S. Murray,et al. Multiple‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double‐Blind Study , 2010, Journal of clinical pharmacology.
[122] J. Chanoine,et al. Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. , 2011, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.
[123] L. Aronne,et al. Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial , 2010, Obesity.
[124] Peter T Katzmarzyk,et al. Relation of body mass index and skinfold thicknesses to cardiovascular disease risk factors in children: the Bogalusa Heart Study. , 2009, The American journal of clinical nutrition.
[125] J. Yanovski. Intensive therapies for pediatric obesity. , 2001, Pediatric clinics of North America.
[126] A. Astrup,et al. The Effect of Tesofensine on appetite , 2012 .
[127] K. Flegal,et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. , 2012, JAMA.
[128] U. Pagotto,et al. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome , 2006 .
[129] Kevin W Lutz,et al. Effectiveness of primary care interventions for weight management in children and adolescents: an updated, targeted systematic review for the USPSTF , 2010 .
[130] R. Jorde,et al. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. , 1996, Diabetes & metabolism.
[131] J. Schwartz,et al. Growth hormone alters lipolysis and hormone-sensitive lipase activity in 3T3-F442A adipocytes. , 1991, Metabolism: clinical and experimental.
[132] J. Swanson,et al. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. , 2002, Pediatrics.
[133] S. Barlow,et al. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. , 2007, Pediatrics.
[134] R. Berkowitz,et al. Weight Loss in Obese African American and Caucasian Adolescents: Secondary Analysis of a Randomized Clinical Trial of Behavioral Therapy Plus Sibutramine , 2007, The Journal of cardiovascular nursing.
[135] A. Starodubova,et al. Complications of obesity in children and adolescents , 2012 .
[136] S. Czernichow,et al. Prevalence of overweight in 6- to 15-year-old children in central/western France from 1996 to 2006: trends toward stabilization , 2009, International Journal of Obesity.
[137] F. Greenway,et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.
[138] T. Wadden,et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. , 2005, The New England journal of medicine.
[139] S. Booth,et al. Effects of Orlistat on Fat‐Soluble Vitamins in Obese Adolescents , 2002, Pharmacotherapy.
[140] Rebecca S. Williamson,et al. The National Health and Nutrition Examination Survey, 1999–2006 , 2011 .
[141] Leila C. Kahwati,et al. Prevention and treatment of overweight in children and adolescents. , 2004, American family physician.
[142] M. Atabek,et al. Use of Metformin in Obese Adolescents with Hyperinsulinemia: A 6-month, Randomized, Double-blind, Placebo-controlled Clinical Trial , 2008, Journal of pediatric endocrinology & metabolism : JPEM.
[143] A. Prentice,et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. , 1999, The New England journal of medicine.
[144] V. Hubbard,et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. , 2002, Obesity research.
[145] Jennifer L Baker,et al. The levelling off of the obesity epidemic since the year 1999 – a review of evidence and perspectives , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[146] J. Lindh,et al. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis , 2011, Journal of psychopharmacology.
[147] D. Maahs,et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. , 2006, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[148] N. Rodger,et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes , 1997, International Journal of Obesity.
[149] C. Scrimgeour,et al. Changes in body composition and energy expenditure after six weeks' growth hormone treatment. , 1991, Archives of disease in childhood.
[150] D. Ferraro,et al. Topiramate in the prevention of pediatric migraine: literature review , 2008, The Journal of Headache and Pain.
[151] M. Thorén,et al. Growth hormone treatment improves body composition in adults with Prader–Willi syndrome , 2003, Clinical endocrinology.
[152] M. Pfister,et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight , 2010, Diabetes, obesity & metabolism.
[153] M. Freemark,et al. The Effects of Metformin on Body Mass Index and Glucose Tolerance in Obese Adolescents With Fasting Hyperinsulinemia and a Family History of Type 2 Diabetes , 2001, Pediatrics.
[154] P. Gorden,et al. Efficacy of leptin therapy in the different forms of human lipodystrophy , 2009, Diabetologia.
[155] L. Aronne,et al. Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity , 2008, Diabetes Care.
[156] M. Flynn,et al. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with ‘best practice’ recommendations , 2006, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[157] E. Salpeter,et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2010, The Cochrane database of systematic reviews.
[158] B. Ozkan,et al. Addition of orlistat to conventional treatment in adolescents with severe obesity , 2004, European Journal of Pediatrics.
[159] J. Swanson,et al. Safety and tolerability of methylphenidate in preschool children with ADHD. , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.
[160] C. Leitão,et al. Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[161] Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. , 2003 .
[162] L. Grummer-Strawn,et al. Relation of body mass index and waist-to-height ratio to cardiovascular disease risk factors in children and adolescents: the Bogalusa Heart Study. , 2007, The American journal of clinical nutrition.
[163] W. Coutinho,et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. , 2005, The Journal of clinical endocrinology and metabolism.
[164] Alicia R. Desilets,et al. Pharmacotherapeutic Options for Overweight Adolescents , 2007, The Annals of pharmacotherapy.
[165] T. Bridger,et al. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. , 2006, Archives of pediatrics & adolescent medicine.
[166] L. Kaplan,et al. Pharmacologic therapies for obesity. , 2010, Gastroenterology clinics of North America.
[167] J. Zhi,et al. The Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents , 2003, Journal of the American College of Nutrition.
[168] N. Weissman,et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.
[169] H. Mehnert. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[170] B. Del-Río-Navarro,et al. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. , 2006, Clinical therapeutics.
[171] Terence Dwyer,et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. , 2011, The New England journal of medicine.
[172] L. Sjöström,et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.
[173] G. Medeiros-Neto,et al. Is DL-fenfluramine a potentially helpful drug therapy in overweight adolescent subjects? , 1994, Obesity research.
[174] S. Toubro,et al. Weight Loss, HbA1c Reduction, and Tolerability of Cetilistat in a Randomized, Placebo‐controlled Phase 2 Trial in Obese Diabetics: Comparison With Orlistat (Xenical) , 2010, Obesity.
[175] S. Heymsfield,et al. Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. , 2002, The Journal of clinical endocrinology and metabolism.
[176] Tanya M. Teslovich,et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index , 2010 .
[177] V. Myllylä,et al. Thyroid Function in Men Taking Carbamazepine, Oxcarbazepine, or Valproate for Epilepsy , 2001, Epilepsia.
[178] Joy Hirsch,et al. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. , 2008, The Journal of clinical investigation.
[179] M. Petzold,et al. Childhood overweight and obesity prevalences levelling off in Stockholm but socioeconomic differences persist , 2008, International Journal of Obesity.
[180] Victor M. Montori,et al. Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion , 2008, The Journal of clinical endocrinology and metabolism.
[181] S. Hercberg,et al. Stabilization of overweight prevalence in French children between 2000 and 2007. , 2009, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.
[182] A. Dulloo,et al. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[183] J. Krakoff,et al. Effects of Metformin on Body Weight and Body Composition in Obese Insulin-Resistant Children , 2011, Diabetes.
[184] E. Ravussin,et al. Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy , 2009, Obesity.
[185] J. Zarzycki,et al. [Effect of mazindol (teronac) on various hormonal indicators in children with simple obesity]. , 1982, Pediatria Polska.
[186] D. Singh-Franco,et al. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta‐analysis , 2011, Diabetes, obesity & metabolism.
[187] V. Montori,et al. Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. , 2008, The Journal of clinical endocrinology and metabolism.
[188] Steven L. Cohen,et al. Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.
[189] S. Bloom,et al. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. , 2008, European journal of endocrinology.
[190] F. Greenway. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent , 2001, Obesity Reviews.
[191] K. Parker,et al. Long-term safety of recombinant human growth hormone in children. , 2010, The Journal of clinical endocrinology and metabolism.
[192] J. Després,et al. Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients , 2008, Diabetes Care.
[193] Linda Koch. Obesity: Taranabant no longer developed as an antiobesity agent , 2010, Nature Reviews Endocrinology.
[194] J. Murray. A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial , 2012 .
[195] Jun-Sing Wang,et al. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. , 2011, Clinical therapeutics.
[196] S. Schinner,et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice , 2009 .
[197] P Kopelman,et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients , 2007, International Journal of Obesity.
[198] M. Westerterp-Plantenga,et al. The effectiveness of long-term supplementation of carbohydrate, chromium, fibre and caffeine on weight maintenance , 1997, International Journal of Obesity.
[199] R. Doleček. Endocrine studies with mazindol in obese patients. , 1980, Pharmatherapeutica.
[200] D. J. Driscoll,et al. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome. , 2006, The Journal of clinical endocrinology and metabolism.
[201] R. Legro. Impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women: do we need a new drug? , 2008, The Journal of clinical endocrinology and metabolism.
[202] S. Murray,et al. Single‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus , 2010, Journal of clinical pharmacology.
[203] R. Rothman,et al. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. , 1999, Circulation.
[204] R. Devos,et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. , 1995, Science.
[205] L. Hayman. Effects of Sibutramine Treatment in Obese Adolescents: A Randomized Trial , 2007 .
[206] L. Kaplan. Pharmacologic therapies for obesity. , 2010, Gastroenterology clinics of North America.
[207] J. Kennedy,et al. The suppression of appetite and food consumption by methylphenidate: the moderating effects of gender and weight status in healthy adults. , 2012, The international journal of neuropsychopharmacology.
[208] J. Yanovski,et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. , 2004, The Journal of clinical endocrinology and metabolism.
[209] C. Cox,et al. Long‐term Weight Control Study VI , 1992 .
[210] M. Goldman,et al. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. , 2006, The Israel Medical Association journal : IMAJ.
[211] O. Pekin,et al. Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. , 2008, Fertility and sterility.
[212] N. Gupta,et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial , 2010, Schizophrenia Research.
[213] Michael Weintraub,et al. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. , 1992, Clinical pharmacology and therapeutics.
[214] C. Boozer,et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial , 2002, International Journal of Obesity.
[215] A. Astrup,et al. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. , 2007, American journal of physiology. Endocrinology and metabolism.
[216] R. Berria,et al. Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone , 2009, Diabetes Care.
[217] P. Shekelle,et al. Meta-Analysis: Pharmacologic Treatment of Obesity , 2005, Annals of Internal Medicine.
[218] P. Janicak,et al. Topiramate plus risperidone for controlling weight gain and symptoms in preschool mania. , 2002, Journal of child and adolescent psychopharmacology.
[219] B. Goldstein,et al. Efficacy and safety of sitagliptin and the fixed‐dose combination of sitagliptin and metformin vs. pioglitazone in drug‐naïve patients with type 2 diabetes , 2011, International journal of clinical practice.
[220] T. Umemura,et al. Severe hepatic injury caused by orlistat. , 2006, The American journal of medicine.
[221] N. Uli,et al. Pharmacotherapy in pediatric obesity: Current agents and future directions , 2009, Reviews in Endocrine and Metabolic Disorders.
[222] M. B. Andelman,et al. Treatment of Obesity in Underprivileged Adolescents , 1967, Clinical pediatrics.
[223] K. Fujioka,et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. , 2007, The Journal of clinical endocrinology and metabolism.
[224] C. White,et al. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. , 2004, JAMA.
[225] D. Allen,et al. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. , 2002, The Journal of clinical endocrinology and metabolism.
[226] E. C. Stein,et al. Long‐term weight control study IV (weeks 156 to 190) , 1992, Clinical pharmacology and therapeutics.
[227] Arya M. Sharma,et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. , 2007, European heart journal.
[228] P. Havel. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin , 2002, Current opinion in lipidology.
[229] W. Klein-Schwartz,et al. Abuse and toxicity of methylphenidate. , 2002, Current opinion in pediatrics.
[230] J Benichou,et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.
[231] B. Zinman,et al. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.
[232] Giuseppe Mancia,et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2009, Blood pressure.
[233] F. Greenway,et al. Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled randomized study. , 2007, The Journal of clinical endocrinology and metabolism.
[234] M. Pelleymounter,et al. Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.
[235] R. Lipp,et al. Chlorphentermine as an Anorexigenic Agent In Adolescent Obesity , 1968, Clinical pediatrics.
[236] D. Chlebna-Sokół,et al. [The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)]. , 1981, Przeglad lekarski.
[237] S. Toubro,et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. , 2002, The American journal of clinical nutrition.
[238] J. Licinio,et al. Ten years of leptin replacement therapy , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[239] J. Yanovski. Behavior therapy and sibutramine for the treatment of adolescent obesity. , 2003, The Journal of pediatrics.
[240] Joseph T. Glessner,et al. Role of BMI‐Associated Loci Identified in GWAS Meta‐Analyses in the Context of Common Childhood Obesity in European Americans , 2011, Obesity.
[241] Valeri Craigle. MedWatch–The FDA Safety Information and Adverse Event-Reporting Program , 2007, Red Book (2012).
[242] M. Nakata,et al. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors , 2008, Regulatory Peptides.
[243] P. Houck,et al. Family-Based Treatment of Severe Pediatric Obesity: Randomized, Controlled Trial , 2009, Pediatrics.
[244] M. Maffei,et al. Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.
[245] Brian E. Saelens,et al. Recommendations for Treatment of Child and Adolescent Overweight and Obesity , 2007, Pediatrics.
[246] Katherine H. Pavlovich,et al. Integrative and Translational Physiology : Integrative Aspects of Energy Homeostasis and Metabolic Diseases Effects of weight loss and leptin on skeletal muscle in human subjects , 2011 .
[247] J. Gosden,et al. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. , 2009, British journal of clinical pharmacology.
[248] Adesh K. Jain,et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. , 2002, Obesity research.
[249] Shu-chen Wu,et al. Topiramate Monotherapy in Newly Diagnosed Epilepsy in Children and Adolescents , 2007, Journal of child neurology.
[250] S. Norgren,et al. Orlistat treatment in obese prepubertal children: a pilot study , 2003, Acta paediatrica.
[251] C. Rock,et al. Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial , 2011, Obesity.
[252] R. Saad,et al. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. , 2002, The Journal of clinical endocrinology and metabolism.
[253] N. Shapira,et al. Topiramate for reversing atypical antipsychotic weight gain. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.
[254] J. Santiago,et al. Leptin concentrations in Prader‐Willi syndrome before and after growth hormone replacement , 2000, Clinical endocrinology.
[255] Jebediah J. Northern,et al. A meta-analysis of family-behavioral weight-loss treatments for children. , 2007, Clinical psychology review.
[256] Sum Lam,et al. Sitagliptin: A Novel Drug for the Treatment of Type 2 Diabetes , 2007, Cardiology in review.
[257] D. Molnár,et al. Presence of metabolic cardiovascular syndrome in obese children , 2000, European Journal of Pediatrics.
[258] A. Mushlin,et al. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. , 1984, Archives of internal medicine.
[259] T. Lobstein,et al. Worldwide trends in childhood overweight and obesity. , 2006, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.
[260] S. Daniels,et al. Cardiovascular Effects of Sibutramine in the Treatment of Obese Adolescents: Results of a Randomized, Double-Blind, Placebo-Controlled Study , 2007, Pediatrics.
[261] R. Townsend,et al. High-fat meals reduce 24-h circulating leptin concentrations in women. , 1999, Diabetes.
[262] R. Padwal. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. , 2009, Current opinion in investigational drugs.
[263] R. Ness-Abramof. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2010 .
[264] G. Bray,et al. Current and potential drugs for treatment of obesity. , 1999, Endocrine reviews.
[265] K. Gadde,et al. Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) , 2011, Obesity.
[266] J. Stockman. Effect of Orlistat on Weight and Body Composition in Obese Adolescents: A Randomized Controlled Trial , 2007 .
[267] D. Lawlor,et al. Obesity in children. Part 1: Epidemiology, measurement, risk factors, and screening , 2008, BMJ : British Medical Journal.
[268] M. Jensen,et al. Effects of growth hormone administration in human obesity. , 2003, Obesity research.
[269] C. Summerbell,et al. Interventions for treating obesity in children. , 2009, The Cochrane database of systematic reviews.
[270] Rass,et al. Phenylpropanolamine and the Risk of Hemorrhagic Stroke , 2000 .
[271] A. Astrup,et al. The Effect of Tesofensine on Appetite Sensations , 2012, Obesity.
[272] G. Frost,et al. Ghrelin enhances appetite and increases food intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.
[273] A. Christopoulos,et al. Amylin receptors: molecular composition and pharmacology. , 2004, Biochemical Society transactions.
[274] C. Mazzoni,et al. Randomized Controlled Trial Evaluating Response to Metformin Versus Standard Therapy in the Treatment of Adolescents with Polycystic Ovary Syndrome , 2005, Journal of pediatric endocrinology & metabolism : JPEM.
[275] C. Fox,et al. Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study , 2012, Obesity.
[276] B. Del-Río-Navarro,et al. Use of sibutramine in obese hispanic adolescents , 2005, Advances in therapy.
[277] N. Fountain. A Pregnant Pause to Consider Teratogenicity of Topiramate , 2009, Epilepsy currents.
[278] E. Waters,et al. Interventions for treating obesity in children (a review)1 , 2007 .
[279] D. Hill,et al. Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance , 2009, Endocrine.
[280] C. Bailey,et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.
[281] Robert V Farese,et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. , 2012, Cell metabolism.
[282] E. Bullmore,et al. Neuropsychiatric Adverse Effects of Centrally Acting Antiobesity Drugs , 2011, CNS neuroscience & therapeutics.
[283] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[284] K. Flegal,et al. Evidence that the prevalence of childhood overweight is plateauing: data from nine countries. , 2011, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.
[285] R. Kelishadi,et al. A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity , 2010, World journal of pediatrics : WJP.